

National Cancer Intelligence Network

Cancer Informatics in the 'new NHS': PHE and NCIN 18 months on....

Mick Peake Clinical Lead, National Cancer Intelligence Network The Health & Social Care Bill 2012: Two New Organisations from April 2013

NHS England

- "The purpose of NHS England is to use the £80bn commissioning budget to secure the best possible outcomes for patients"
- To ensure the whole commissioning architecture is in place; will also commission some services directly

Public Health England (PHE)

- Information & Intelligence to support local PH and public making healthier choices
- National Leadership to PH, supporting national policy
- Development of PH workforce
- A civil service function, not NHS



Data Drivers

- Government
 - A spotlight on the role of data and transparency
- Commissioning
 - NHS Outcomes Framework
- Regulation
 - New regulation framework (CQC & Monitor)
- The 'public', patients and families
 - (e.g. 'Friends and family test')



Providers of information in the new NHS

- Main sources/providers
 - Health & Social Care Information Centre (HSCIC)
 - National Audits
 - ONS
 - PHE (Civil Service)- Cancer Registries
 - NHS England Business Intelligence Teams (ATS/CSU)
- Information Intermediaries (e.g. CRUK, Dr Foster, MacMillan)



Public Health England



Knowledge Directorate

- National Cancer Registration Service
- Analytical workforce from 8 registries moved into regional Knowledge and
 - Intelligence Teams (KITs)
 - SSCRG Lead Area Work Programmes
 - Local contribution
- Health Intelligence Networks (HINs):
 - Mental Health, Maternal & Child Health, Cardiovascular & Diabetes, End of Life, NCIN

Public Health England: Emerging 'Intelligence' Structures

Public Health England Chief Knowledge Officer (Prof. John Newton)

Disease Registration Service (Dr Jem Rashbass) Health Intelligence Networks (Prof. Brian Ferguson)

Knowledge & Intelligence Teams (KITs)


National Cancer Intelligence Network Chris Carrigan PHE Information Services Chris Carrigan



The English National Cancer Registration System

- Comprehensive data collection and quality assurance over the entire cancer care pathway on all patients treated in England
- Single national system across England
- Routine electronic sources in registry practice
- Single integrated workforce split off from the analytical work force
- Director of Disease Registration
- Evolving operational links with hospital leads
- Pan-England roll-out completed September 2013








NCRS – ENCORE

(English National Cancer Online Registration Environment)



NHS England – current structures

- One national office in Leeds
- 4 regions, directly commission primary care & specialist services
- **10** specialised commissioning hubs within **27** Area Teams
- 12 clinical senates clinical advice/leadership at strategic level to CCGs and HWBs
- **12** strategic Clinical Networks (up to 5 years)
- **12** Academic Health Science Networks
- **18** Commissioning Support Units support to CCGs
- **27** Area Teams will support CCG development
- 211 Clinical Commissioning Groups (CCGs)
- 152 Health and Well Being Boards



Specialist Commissioning

 National Service Specifications (e.g. radiotherapy, chemotherapy, mesothelioma, upper GI cancer, specialised urology, surgery....)

Clinical Reference Groups - 12 relating to cancer (e.g. chemotherapy, radiotherapy, upper GI surgery, thoracic surgery......)

.....under review

Clinical Reference Groups - cancer

- Radiotherapy Peter Kirkbride and Adrian Crellin
- PET-CT Wai Lup Wong
- Specialised Cancer Sean Duffy
- Blood and Marrow transplantation Antonio Pagliuca
- Thoracic surgery Richard Page
- Upper GI Surgery William Allum
- Sarcoma Jeremy Whelan
- CNS tumours Paul Grundy
- Specialised urology Vijay Sangar
- Complex gynaecological services vacant
- Chemotherapy Peter Clark
- Complex Head & Neck Peter Thomson
- Teenage and Young People Cancer Rachael Hough

NHS Outcome Framework 2013/14 Dashboard

1 Preventing people from dying pre-	naturely			3 Helping people to recover from epice						
					1 Preventing people from dying prematurely					
Overarohing indicators	Latest data	Indicator	Unit	Overarching indicators						
1a.I Potential Years of Life Lost (PYLL) from		value		3a Emergency admissions for acute	Overarching indicators					
causes considered amenable to health care -	2011	M - 2,157 F - 1,700	per 100,000 population	conditions that should not usually require			Indicator			
Adults	2011	M-618	per 100.000	hospital admission (all ages) 3b Emergency readmissions within 30 days of		Latest data	value	Unit		
1a.II Children and young people		F-531	population	discharge from hospital	1a.i Potential Years of Life Lost (PYLL) from		Vulue			
1b.I Life expectancy at 75 - Males 1b.II Life expectancy at 75 - Females	2010 2010	11.3	period expectations of life - years	Improvement areas			M - 2,157	per 100.000		
Improvement areas				3.1.1 Total health gain as assessed by patients for elective procedures - Hip replacement	causes considered amenable to health care -	2011	F - 1,700	population		
 1.1 Under 75 mortality rate from cardiovascular disease 	2011	58.0	per 100,000 population		Adults		1 - 1,700	population		
1.2 Under 75 mortality rate from respiratory	2011	23.5	per 100,000	3.1.II – Knee replacement		2011	M - 616	per 100.000		
lisease			population per 100,000	3.1.III – Groin hemia	1a.ii - Children and young people					
1.3 Under 75 mortality rate from liver disease	2011	14.9	population	3.1.Iv - Varicose veins			F - 531	population		
1.4 Under 75 mortality rate from cancer	2011	107	per 100,000 population		1b.i Life expectancy at 75 - Males	2010	11.3	period expectations of		
1.4.1 One-year survival from colorectal				3.1.v – Psychological therapies 3.2 Emergency admissions for children with	1b.ii Life expectancy at 75 - Females	2010	13.1	life - years		
cancer " 1.4.II Five-year survival from colorectal	2008-2010_11	74.4	*	lower respiratory tract infections		2010	10.1			
1.4.II Five-year survival from colorectal cancer "	2008-2010_11	55.3	*	s.s An indicator on recovery from injunes and trauma	a indicator on recovery from injunes and Improvement areas					
1.4.III One-year survival from breast	2008-2010 11	95.5	% female	3.4 Proportion of stroke patients reporting an	1.1 Under 75 mortality rate from	2011	58.0	per 100,000		
cancer " 1.4.Iv Five-year survival from breast				Improvement in activity/lifestyle on the	cardiovascular disease	2011	0.00	population		
cancer "	2008-2010_11	84.3	% female	Modified Rankin Scale at 6 months	1.2 Under 75 mortality rate from respiratory			per 100,000		
1.4.v One-year survival from lung cancer " 1.4.vl Five-year survival from lung cancer "	2008-2010_11 2008-2010_11	31.8 9.8	*	3.6.1 Proportion of patients with a fragility fracture recovering to their previous levels of		2011	23.5	• •		
1.6 Excess under 75 mortailty rate in adults	2006-2010_11	921	absolute gap per	mobility at 30 days	disease			population		
with serious mental liness			100,000 population	3.5.II Proportion of patients with a fragility		2044	44.0	per 100,000		
1.6.1 Infant mortality 1.6.1 Neonatal mortality and stillbirths	2011 2011	42	per 1,000 births per 1,000 births	fracture recovering to their previous levels of mobility at 120 days	1.3 Under 75 mortality rate from liver disease	2011	14.9	population		
8.III Five-year survival from all cancers in Indicator to be developed 3.8.				3.8.1 Proportion of older people (65 and over)						
children 1.7 Excess under 60 mortailty rate in adults				who were still at home 91 days after discharge from hospital into reablement/rehabilitation	1.4 Under 75 mortality rate from cancer	2011	107	per 100,000		
with a learning disability	Indicator to be developed			services	in onder romentality rate from cancer			population		
				3.8.II Proportion offered rehabilitation following	1.4.i One-year survival from colorectal		74.4			
2 Enhancing quality of life for people with long-term conditions discharge from acute or community h					cancer *	2006-2010_11	74.4	%		
				++						
Overarching Indicators		Indicator		-	1.4.ii Five-year survival from colorectal	2006-2010 11	55.3	%		
	Latest data	value	Unit		cancer *	2000-2010_11	33.5	70		
2 Health-related quality of life for people with long-term conditions	Jul12-Mer13	0.73	avg EQ-5D score		1.4.iii One-year survival from breast					
improvement areas				t		2006-2010_11	95.5	% female		
2.1 Proportion of people feeling supported to manage their condition	Jul12-Mer13	69.3	*	NHS Outcomes	cancer					
2.2 Employment of people with long-term	Jan-Mar13	11.8	% gep		1.4.iv Five-year survival from breast	2006-2010 11	84.3	% female		
conditions	Jan-Mar 13	11.0	76 gap	ł	cancer *	2000-2010_11	84.3	% iemaie		
2.3.1 Unplanned hospitalisation for chronic	2011/12	801	per 100,000		1.4.v One-year survival from lung cancer *	2006-2010 11	31.6	%		
ambulatory care sensitive conditions (all ages)			population	* Deta displayed are for 2012/13 indicators as data for		_				
2.3.11 Unplanned hospitalisation for asthma, diabetes and epilepsy in under 19s	2011/12	321	per 100,000 population	svalable	1.4.vi Five-year survival from lung cancer *	2006-2010_11	9.8	%		
2.4 Health-related quality of life for carers	Jul12-Mer13	0.8	svg EQ-5D score	t	1.5 Excess under 75 mortality rate in adults	2040/44	024	absolute gap per		
2.6 Employment of people with mental liness	Jan-Mar13	39.0	% gap		with serious mental illness	2010/11	921	100,000 population		
2.8.I Estimated diagnosis rate for people with	2011/12	48.0	*	t		2011	4.2			
dementia 2.8.II A measure of the effectiveness of post-	201012	40.0	~	20XX indicates calendar year	1.6.i Infant mortality	2011		per 1,000 births		
diagnosis care in sustaining independence				20XX indicates calendar year 20XX/XX indicates financial year	1.6.ii Neonatal mortality and stillbirths	2011	8.2	per 1,000 births		
and improving quality of life				L The second sec	1.6.iii Five-year survival from all cancers in	Indicator to be developed				
					children	Indicator to be developed				
					i i i i i i i i i i i i i i i i i i i					

Clinical Commissioning Group Outcomes Indicator Set


2013/14 under 75 mortality rate from cancer

- 1 and 5 year survival from all cancers
- 1 and 5 year survival from breast, lung & colorectal cancers

2014/15 additional indicators for cancer

- cancers diagnosed via emergency routes
- 5 year survival children
- cancer stage at diagnosis
- cancers detected at stage 1 or 2
- 1 and 5 yr survival for lung, breast and colorectal cancers

HSCIC Indicator Portal



Datasets

- Radiotherapy Dataset (RTDS), 2009.....
- Diagnostic Imaging Dataset (DIDs), 2012...
- Systemic Anti-Cancer Therapy Dataset (SACT), 2012....
- Cancer Outcomes & Services Dataset (COSD), 2013.....




Examples of the clinical value of new data

- Demonstration of variation
- Teasing out the causes of variation
- Demonstrating value of specialisation
- Building data into quality improvement
- Adding outcome data into Peer Review
- Providing robust evidence behind National Guidelines and Quality Standards (NICE)
- Supporting 'intelligent commissioning'





NCRS BiobankLink Service





- National Lung, Colo-rectal and Head & Neck Cancer Audits all have contracts that expire at the end of 2014

Re-tendering process underway – smooth transition will be the main issue

- New Prostate Cancer Audit began 2014
- Breast cancer audit likely to be commissioned in 2015







- New model for national cancer audits
 - Partnership between NCRS and professional bodies
- Information governance and data QA managed by NCRS
 - Near-real-time data collection from MDTs
 - Data set largely collected as part of routine flows
- Continuous feedback to clinicians and MDTs
- NCRS produces linked audit datasets for analysis

Feeding back: examples



Public Health England

- E Atlas
- Reports and data briefings
- Cancer Commissioning Toolkit
- Service & GP Profiles Sue Knights



← → C 🗋 www.ncin.org.uk/cancer_information_tools/eatlas/network/atlas.html?select=Eav&indicator=i0

UK Cancer e-Atlas by cancer networks

76 - TTTT

72

Data being displayed: Prostate - Male Survival 5 Year

Guide	Print	Select localities	Go to health boundar	ry e-Atlas				na int	tional cancer elligence network
	Save	Export data	Select cancer type below (use -/+ at bottom to expand the whole list)						
	Select cancer network	Rate 0	Cancer type	Locality	No.Cases/Deaths	Rate/%	UK avge	Comparator to UK average	rate 🔳 🛙
Essex		82.9 %	All cancers combined						
Greater Manchester	and Cheshire	81.4 %	▶ Bladder						
Greater Midlands		80.2 %	▶ Brain						
Humber and Yorksh	ire Coast	80.5 %	▶ Breast						
Kent and Medway		81.9 %	► Cervix						
Lancashire and Sou	th Cumbria	85.4 %	Colorectal (bowel)						
Merseyside and Che	eshire	82.0 %	▶ Kidney						
Mount Vernon		78.9 %	 Leukaemia 						
North East London		81.5 %	Lung including trachea and bronchus						
North London		87.1 %	 Malignant melanoma of skin 						
North Trent		74.4 %	Non-Hodgkin lymphoma						
North West London		86.4 %	 Oesophagus 						
North of England		79.9 %	 Ovary 						
North of Scotland		80.8 %	 Pancreas 						
Northern Ireland		82.9 %	V Prostate						
Pan Birmingham		86.5 %	Male Incidence*	North of England	1,697	86.3 🔳	100.5	0	150
Peninsula		79.2 %	Male Mortality*	North of England	538	24.7 •	24.0		80
Scotland		80.1 %	Male Survival 1 Year	North of England	-	95.4 % ♦	95.0 %		100
South East London		81.5 %	Male Survival 3 Year	North of England	-	86.3 %	87.8 %	0	100
South East Scotland		82.2 %	Male Survival 5 Year	North of England		79.9 %	82,2 %	0	100
South West London		87.8 %	 Stomach 			1515 14	0212 70		
Surrey, West Susse	x and Hampshire	83.7 %	 Uterus 						
Sussex		82.8 %	P Oterus						
Thames Valley		88.0 %							
United Kingdom		82.2 %	North of England						
Wales		76.6 %		Not significantly different than UK averag	e 🔶 Significantly higher than UK averag	je 🔸			
West of Scotland		78.2 %	UK average Data value • Incidence Mortality Survival						
Yorkshire Cancer Ne	etwork	82.0 %	- +						
Network rates			Information about the selected data ite	m					* Age-standardise
96 -		= 0	Five-year relative survival estimate, n	nales, ICD10 C61 : Prostate, 2000-2004					= 0
			Relative survival is an estimate of the	percentage of patients still alive five year	s on from their diagnosis with prostate o	ancer, taking into accou	int the background mort	tality in the general population. It is therefo	ore an estimate of the
92 -		- •	percentage of patients who survive the						
88 -			Data definitions:						
84				based on people diagnosed during 2000	-2004. Relative survival estimates show	vn above are not age-st	andardised.		
80 TT			Current Mathematic Control Tata Program	hunde (NOTN) UK Channe Tafaran Vice Car	(UKCIC)				
~ _T 1				twork (NCIN), UK Cancer Information Serv					

Source: National Cancer Intelligence Network (NCIN), UK Cancer Information Service (UKCIS), accessed May 2011. for more detailed information and definitions please see the Cancer e-Atlas Guide.








National Cancer Intelligence Network Cancer survival in England by stage

www.ncin.org.uk




Figure 2, one-year survival, all stage, by year of diagnosis, not standardised by age



With Realth England


Figure 4 One-year relative/net survival, by stage, in the ICBP and England 2012 data





← → C A https://www.cancertoolkit.co.uk ☆ 🌒 🗉 NCIN(A) Cancer ommissioning Charts **Public users** 0 Members login Charts are displayed using Example Chart A 🙂 figures or percentages Detail of Example Chart A and comply with data Email sharing rules to ensure patient confidentiality. Password Forgotten your password? Login Types of Data Available - Incidence; Mortality; Survival; Smoking Cessation; Peer Review; Screening; Referrals; Waiting Times; Radiotherapy; National Audit; Not registered yet? Cancer medicines; Place of death; Programme Budgeting. How do I register? **Register Now** Contact Us

www.ncin.org.uk



www.ncin.org.uk






Mick Peake *

Home Service Specifications Profiles Charts

Home / Charts / Emergency Presentation / Proxy measure for emergency presentations for cancer



Updates





- Split of cancer registration and analytical services, with loss of experienced personnel
- Loss of links with NHS (Cancer Policy Team, National Cancer Action Team, NHS Improvement)
- Loss of old Cancer Network / PCT links
- Uncertainty around roles and responsibilities
- Loss of focus on cancer
- Current review of just about everything!

Conclusions

•The quality and range of clinically relevant data on cancer is increasing rapidly

•High quality population-based data can clearly drive clinical behavioural change

•We now have a large and expanding clinical community engaged with cancer data

•Feedback and ongoing interaction with clinicians is an essential part of the process – peer pressure is powerful

•There is a need to improve how information is used at a local level

•The collection and intelligent use of data are at the heart

of good clinical practice and commissioning



Requesting Access to Data

Through the Office of Data Release (ODR) which:

- 1. Has oversight of all ad-hoc data requests and releases
- 2. Ensures that all requests are logged and then tracked
- 3. Determines the appropriateness of data releases where the data is identifiable or potentially identifiable
- Ensures that appropriate controls are placed on data recipients to maintain the security and confidentiality of PHE information



Requesting Access to Data (2)

The ODR meets weekly to decide the outcome of data requests. Within 2 weeks of receiving your initial request, you will be informed of one of three outcomes:

- •Request accepted
- •Further information needed request to be resubmitted
- •Request declined

Copyright © 2014 by the International Consortium for Health Outcomes Measurement. All rights reserved. 33